May 2012

Failure of Intravenous Cidofovir for Generalized Verrucosis in a Patient With Severe Combined Immunodeficiency

Author Affiliations

Author Affiliations: Department of Dermatology, Venereology, and Allergology, Ruhr-University Bochum, Bochum, Germany (Drs Potthoff and Kreuter); Institute of Virology, National Reference Center for Papilloma- and Polyomaviruses, University of Cologne, Cologne, Germany (Dr Wieland).

Arch Dermatol. 2012;148(5):659-660. doi:10.1001/archdermatol.2012.22

Generalized verrucosis (GV) is a term that encompasses a spectrum of human papillomavirus (HPV)–associated skin lesions that predominantly occur in genetic or immunodeficiency diseases.1 Conventional ablative or topical treatment options for GV are often unsatisfactory. Some years ago, a complete and durable clearance of recalcitrant cutaneous warts following intravenous cidofovir treatment in a patient with human immunodeficiency virus (HIV) infection was reported in the Archives.2 Moreover, a recent case report published in the Archives demonstrated the efficacy of intravenous cidofovir in giant molluscum contagiosum in an HIV-positive man.3 These observations encouraged us to initiate intravenous cidofovir for GV in a patient with severe combined immunodeficiency (SCID).

First Page Preview View Large
First page PDF preview
First page PDF preview